Looking forward to the exciting collaboration between @KidneyCancer and @ASTRO_org at the annual #IKCS meeting in Dallas. Join me and my fellow panelists as we explore current and innovative approaches to treating kidney cancer with radiation @OncoAlert
Amazing work led by Stepan and @PavlosMsaouel employing novel prognostic modeling techniques in the largest cohort of patients with #renalmedullarycarcinoma
A benefit of working with @PavlosMsaouel is that we treat many variant RCCs. Renal Medullary Carcinoma is one such variant (0.5% of RCC), which has remarkably different RT sensitivity. MDT to 30gy/5 often achieves a CR and with minimal toxicity even with high dose chemo.
🩺 The evolving role of SBRT in metastatic kidney cancer
At the 2nd Florence International Consensus, Prof. Chad Tang from @UTMDAnderson highlights how stereotactic body radiotherapy (SBRT) is becoming an increasingly important part of metastatic renal cell carcinoma (RCC) management. #FlorenceConsensus26
🎯 Oligometastatic disease SBRT may help defer systemic therapy and its associated side effects in selected patients. Local treatment approaches—including radiotherapy, surgery and interventional ablation—offer options that work through mechanisms distinct from systemic therapy.
🔬 Oligoprogressive disease By targeting a limited number of progressing lesions, SBRT may allow patients to remain on their current systemic treatment for longer, potentially delaying the need to switch to subsequent lines of therapy.
💡 The key takeaway: Across the metastatic disease spectrum, SBRT is expanding the role of local treatment in kidney cancer care, supporting more tailored treatment strategies and helping clinicians consider how best to manage disease progression while preserving treatment options.
📍 As evidence and clinical experience continue to evolve, multidisciplinary decision-making remains essential to identifying the patients most likely to benefit.
#KidneyCancer@Lucarecco@CarlottaB@RobClarkeLab@JavierCortesMD@curijoey@delmastro_lucia@ALEDIGNUS12@Prof_Nadia_H@ClareIsacke@reshmajagsi@KaidarOrit@AnnaKirby17@matteolambe@Icro_Meattini@hoperugo@TanjaSpanic@MassimoDiMaio75@Silke_Gillessen@DrRanaMcKay@brian_rini@alison_tree@ChadTangMD@DrYukselUrun@MicheleAquilano@GiulioFrancoli1@DrDanielHeng
1/6:
I am excited to share our multi-institutional F-SHARP phase I/II trial, now published in @JCO_ASCO!
doi.org/10.1200/JCO-25-02730
There are limited prospective data defining the optimal management of intraprostatic radiorecurrence (IPR) after definitive RT for prostate cancer.
We asked:
1. Is dose-escalated focal salvage high dose rate brachytherapy safe and effective for IPR?
2. Can Decipher (@Veracyte) identify patients with higher risk of recurrence with salvage ReRT that may benefit from therapeutic intensification?
🧵👇